Bacteriophages as New previously overlooked Human Viral Pathogens

Bacteriophages are previously overlooked triggers of neurodegeneration and autoimmunity

Implying bacteriophages as novel therapeutic targets to breakthrough neurodegeneration and autoimmunity

Tetz Laboratories

By highlighting bacteriophages as novel therapeutic targets for the discovery and development of medical products, TETZ LABORATORIES has established a unique pipeline of drug candidates for neurodegenerative and autoimmune pathologies.

TETZ LABORATORIES is a pioneering microbiome company employing various proprietary technologies to develop breakthrough  therapeutics and diagnostic tools.

Our mission

Tetz Laboratories is conducting cutting-edge microbiome research fueled by a one-of-a-kind scientific team with a broad multidisciplinary approach.

Our latest discoveries provide us with the ability to rethink how we treat and prevent neurodegenerative and autoimmune diseases and to bring their therapy to a new level of efficacy based on our discovery of bacteriophages as new human viral pathogens and novel therapeutic targets

Diagnosis
Diagnosis
The first microbiome- and phagobiome-based predictive test to determine if a patient will develop T1D.
Prevention
Prevention
The discovery of bacteriophages’ implication in T1D as a novel and previously unknown agent would provide us for the first time with the ability to reassess the nature of this disease and how we treat and prevent T1D
Therapy
Therapy
HMI develops a novel therapeutic paradigm for T1D
The science
About us
Pipeline
Publications
Year of Publication: 2018
Journal: Scientific Reports
Year of Publication: 2018
Journal: Microorganisms MDPI
Year of Publication: 2017
Journal: Frontiers in Microbiology
Year of Publication: 2017
Journal: Scientific Reports
view more